# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-137915
Filing Date
2026-04-01
Accepted
2026-04-01 16:14:56
Documents
16
Period of Report
2026-05-19

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | vktx-20260401.htm iXBRL | DEF 14A | 1489665
2 | GRAPHIC | img12074702_0.jpg | GRAPHIC | 103118
3 | GRAPHIC | img12074702_1.jpg | GRAPHIC | 83453
4 | GRAPHIC | img12074702_2.jpg | GRAPHIC | 180291
5 | GRAPHIC | img12074702_3.jpg | GRAPHIC | 172318
| Complete submission text file | 0001193125-26-137915.txt |  | 4125139

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | vktx-20260401.xsd | EX-101.SCH | 8927
19 | EXTRACTED XBRL INSTANCE DOCUMENT | vktx-20260401_htm.xml | XML | 504245

Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37355 | Film No.: 26828323
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)